|
4/17/2013 7:01:57 AM
|
Lorus Therapeutics Signs Research And License Option Agreement With Elanco
|
|
4/12/2013 5:04:03 PM
|
Lorus Therapeutics Posts Q3 Loss Per Share Of C$0.03 Vs. Loss C$0.05 Year Ago
|
|
4/10/2013 7:02:23 AM
|
Lorus Therapeutics Presents Biomarker Data For LOR-253 At 2013 AACR Annual Meeting
|
|
3/5/2013 7:00:52 AM
|
Lorus Therapeutics Announces Allowance Of Chinese Patent For Anticancer Drug LOR-253
|
|
1/22/2013 7:04:58 AM
|
Lorus Therapeutics Says Gets U.S. Patent For Cancer Therapy IL-17E
|
|
1/14/2013 7:55:32 PM
|
Lorus Therapeutics Posts Q2 Loss Per Share Of C$0.04 Vs Loss C$0.07 Last Year
|
|
1/7/2013 7:04:08 AM
|
Lorus Therapeutics Announces Successful Dose Escalation Of Phase I Clinical Trial Of LOR-253
|
|
12/18/2012 7:02:29 AM
|
Lorus Therapeutics, Brock University Sign Collaboration Deal To Develop Novel Anticancer Drugs
|
|
10/15/2012 5:04:45 PM
|
Lorus Therapeutics Posts Q1 Loss Per Share Of C$0.03 Vs. Loss C$0.06 Year Go
|
|
8/29/2012 2:30:19 PM
|
|
|
8/29/2012 8:04:41 AM
|
Lorus Therapeutics Says Gets Funding From Canadian Govt. For Development Of Cancer Therapy IL-17E
|
|
8/14/2012 7:01:03 AM
|
Lorus Therapeutics Unveils Issuance Of Patent In Japan For Anticancer Drug LOR-253 And Antimicrobial Drug LOR-220
|
|
8/8/2012 7:10:09 AM
|
Lorus Therapeutics FY12 Loss/Share Narrows To C$0.23 From C$0.38 Last Year
|
|
6/28/2012 7:08:48 AM
|
|
|
6/28/2012 7:05:34 AM
|
Lorus Therapeutics Unveils Issuance Of Canadian Patent For Novel Anticancer Therapy IL-17E
|
|
6/28/2012 7:03:22 AM
|
Lorus Therapeutics Announces Issuance Of Canadian Patent For Novel Anticancer Therapy IL-17E
|